[EN] HETEROCYCLYL-PYRIDINYL-BASED BIPHOSPHONIC ACID, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF [FR] ACIDE HÉTÉROCYCLYLE-PYRIDINYLE BISPHOSPHONIQUE, SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, COMPOSITION EN CONTENANT ET SON PROCÉDÉ D'UTILISATION
[EN] HETEROCYCLYL-PYRIDINYL-BASED BIPHOSPHONIC ACID, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF [FR] ACIDE HÉTÉROCYCLYLE-PYRIDINYLE BISPHOSPHONIQUE, SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, COMPOSITION EN CONTENANT ET SON PROCÉDÉ D'UTILISATION
HETEROCYCLYL-PYRIDINYL-BASED BIPHOSPHONIC ACID, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF
申请人:Tsantrizos Youla S.
公开号:US20130203702A1
公开(公告)日:2013-08-08
The present invention relates to novel compounds, compositions containing same and methods for inhibiting human farnesyl pyrophosphate synthase or for the treatment or prevention of disease conditions using said compounds;
Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
申请人:Tsantrizos Youla S.
公开号:US08816082B2
公开(公告)日:2014-08-26
The present invention relates to novel compounds, compositions containing same and methods for inhibiting human farnesyl pyrophosphate synthase or for the treatment or prevention of disease conditions using said compounds;
[EN] HETEROCYCLYL-PYRIDINYL-BASED BIPHOSPHONIC ACID, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF<br/>[FR] ACIDE HÉTÉROCYCLYLE-PYRIDINYLE BISPHOSPHONIQUE, SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, COMPOSITION EN CONTENANT ET SON PROCÉDÉ D'UTILISATION
申请人:UNIV MCGILL
公开号:WO2011147038A1
公开(公告)日:2011-12-01
The present invention relates to novel compounds, compositions containing said compounds and methods for inhibiting human farnesyl pyrophosphate synthase or for the treatment or prevention of disease conditions using said compounds, which may also be useful in the inhibition of FPPS enzymes of microorganisms and protozoan parasites such as the groups of Leishmania, Plasmodium, Trypanosoma, Toxoplasma and Cryptosporidium.